Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of January 2017, with the report dated January 3, 2017. The filing primarily announces a significant capital raise through an investment agreement and a change in board composition.
Key Financial Metrics
The filing does not provide standard financial statements such as revenue, profit, cash flow, or operating margins. The primary financial data relates to a specific financing transaction:
- Investment Amount: NIS 10,904,749 (approximately US$2.8 million).
- Shares Issued: 33,760,832 ordinary shares (equivalent to approximately 844,000 ADSs).
- Price Per Share: NIS 0.323 (based on the TASE closing price on December 29, 2016).
- Dilution Impact: The new shares represent 19.99% of issued and outstanding capital immediately post-issuance and 12.08% on a fully diluted basis.
Material Changes
The most material change reported is the entry into an investment agreement with Angels Investments in Hi Tech Ltd., controlled by Mr. Marius Nacht. This transaction significantly alters the company's capital structure and liquidity position. Additionally, the Board appointed Mr. Isaac Devash as a new director, effective January 11, 2017, replacing Professor Liora Katzenstein whose term ended.
Outlook, Risks, and Contingencies
Restrictions on Shares: The newly issued shares are subject to trading restrictions under Israeli Securities Law. The investor is prohibited from selling shares for six months. Subsequently, sales are limited to 1% of issued capital per quarter over six calendar quarters, capped by average daily trading volume.
Regulatory Status: The shares are not registered under the U.S. Securities Act of 1933 and cannot be offered or sold in the United States unless registered or an exemption applies. A legend will be placed on the shares indicating these transfer prohibitions.
Management Commentary: The filing notes that the investment amount is contingent upon Board approval and approval by the Tel Aviv Stock Exchange (TASE).
Investor Verification Checklist
- Verify the final closing of the NIS 10.9 million investment and the actual issuance of 33.76 million shares.
- Confirm the appointment of Mr. Isaac Devash to the Board of Directors.
- Monitor the trading restrictions and lock-up periods applicable to the new investor's shares.
- Review the attached press release (Exhibit 99.1) for additional details on the use of proceeds.
- Note that the filing does not contain updated operational or clinical trial data for the company's immunotherapeutics pipeline.